Abstract
To develop a potent hypoxia-inducible promoter, we evaluated the usefulness of chimeric combinations of the (Egr-1)-binding site (EBS) from the Egr-1 gene, the metal-response element (MRE) from the metallothionein gene, and the hypoxia-response element (HRE) from the phosphoglycerate kinase 1 gene. In transient transfection assays, combining three copies of HRE (3 × HRE) with either EBS or MRE significantly increased hypoxia responsiveness. When a three-enhancer combination was tested, the EBS–MRE-3 × HRE (E–M–H) gave a hypoxia induction ratio of 69. The expression induced from E–M–H-pGL3 was 2.4-fold higher than that induced from H-pGL3 and even surpassed the expression from a human cytomegalovirus promoter-driven vector. The high inducibility of E–M–H was confirmed by validation studies in different cells and by expressing other cDNAs. Gel shift assays together with functional overexpression studies suggested that increased levels of hypoxia-inducible factor 1α, metal transcription factor-1 and Egr-1 may be associated with the high inducibility of the E–M–H chimeric promoter. E–M–H was also induced by hypoxia mimetics such as Co2+ and deferoxamine (DFX) and by hydrogen peroxide. Gene expression from the E–M–H was reversible as shown by the reduced expression of the transgene upon removal of inducers such as hypoxia and DFX. In vivo evaluation of the E–M–H in ischemic muscle revealed that erythropoietin secretion and luciferase and LacZ expression were significantly higher in the E–M–H group than in a control or H group. With its high induction capacity and versatile means of modulation, this novel chimeric promoter should find wide application in the treatment of ischemic diseases and cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Guillemin K, Krasnow MA . The hypoxic response: huffing and HIFing. Cell 1997; 89: 9–12.
Boast K, Binley K, Iqball S, Price T, Spearman H, Kingsman S et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197–2208.
Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD . Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002; 9: 1403–1411.
Su H, Arakawa-Hoyt J, Kan YW . Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 2002; 99: 9480–9485.
Shibata T, Giaccia AJ, Brown JM . Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4: 40–48.
Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S et al. Hypoxia-mediated tumour targeting. Gene Therapy 2003; 10: 540–549.
Shibata T, Giaccia AJ, Brown JM . Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy 2000; 7: 493–498.
Murphy BJ, Andrews GK, Bittel D, Discher DJ, McCue J, Green CJ et al. Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res 1999; 59: 1315–1322.
Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 2001; 61: 2696–2703.
Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999; 274: 15030–15040.
Saydam N, Georgiev O, Nakano MY, Greber UF, Schaffner W . Nucleo-cytoplasmic trafficking of metal-regulatory transcription factor 1 is regulated by diverse stress signals. J Biol Chem 2001; 276: 25487–25495.
Lee SL, Tourtellotte LC, Wesselschmidt RL, Milbrandt J . Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem 1995; 270: 9971–9977.
Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000; 6: 1355–1361.
Okada M, Wang CY, Hwang DW, Sakaguchi T, Olson KE, Yoshikawa Y et al. Transcriptional control of cardiac allograft vasculopathy by early growth response gene-1 (Egr-1). Circ Res 2002; 91: 135–142.
Ohtani K, Egashira K, Usui M, Ishibashi M, Hiasa KI, Zhao Q et al. Inhibition of neointimal hyperplasia after balloon injury by cis-element ‘decoy’ of early growth response gene-1 in hypercholesterolemic rabbits. Gene Therapy 2004; 11: 126–132.
Lee YS, Jang HS, Kim JM, Lee JS, Lee JY, Kim KL et al. Adenoviral-mediated delivery of early growth response factor-1 gene increases tissue perfusion in a murine model of hindlimb ischemia. Mol Ther 2005; 12: 328–336.
Gong P, Hu B, Stewart D, Ellerbe M, Figueroa YG, Blank V et al. Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells: regulation by Nrf2 and MafG transcription factors. J Biol Chem 2001; 276: 27018–27025.
Zhu H, Bunn HF . Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 1999; 115: 239–247.
Gill G, Ptashne M . Negative effect of the transcriptional activator GAL4. Nature 1988; 334: 721–724.
Flanagan PM, Kelleher III RJ, Sayre MH, Tschochner H, Kornberg RD . A mediator required for activation of RNA polymerase II transcription in vitro. Nature 1991; 350: 436–438.
Cahill MA, Ernst WH, Janknecht R, Nordheim A . Regulatory squelching. FEBS Lett 1994; 344: 105–108.
Jang HS, Kim HJ, Kim JM, Lee YS, Kim KL, Kim JA et al. A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle. Mol Ther 2004; 9: 464–474.
Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114–1123.
Tio RA, Tkebuchava T, Scheuermann TH, Lebherz C, Magner M, Kearny M et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999; 10: 2953–2960.
Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT et al. Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121). Gene Therapy 2004; 11: 512–521.
Marples B, Greco O, Joiner MC, Scott SD . Molecular approaches to chemo-radiotherapy. Eur J Cancer 2002; 38: 231–239.
Greco O, Marples B, Joiner MC, Scott SD . How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197: 312–325.
Small S, Arnosti DN, Levine M . Spacing ensures autonomous expression of different stripe enhancers in the even-skipped promoter. Development 1993; 119: 762–772.
Nikolajczyk BS, Cortes M, Feinman R, Sen R . Combinatorial determinants of tissue-specific transcription in B cells and macrophages. Mol Cell Biol 1997; 17: 3527–3535.
Vaupel P, Schlenger K, Knoop C, Hockel M . Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51: 3316–3322.
Brown JM, Wilson WR . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437–447.
Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S . An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721–1727.
Harris AL . Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38–47.
Zhang B, Georgiev O, Hagmann M, Gunes C, Cramer M, Faller P et al. Activity of metal-responsive transcription factor 1 by toxic heavy metals and H2O2 in vitro is modulated by metallothionein. Mol Cell Biol 2003; 23: 8471–8485.
Lim CP, Jain N, Cao X . Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 1998; 16: 2915–2926.
Chun YS, Lee KH, Choi E, Bae SY, Yeo EJ, Huang LE et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res 2003; 63: 8700–8707.
Stuart GW, Searle PF, Chen HY, Brinster RL, Palmiter RD . A 12-base-pair DNA motif that is repeated several times in metallothionein gene promoters confers metal regulation to a heterologous gene. Proc Natl Acad Sci USA 1984; 81: 7318–7322.
Stuart GW, Searle PF, Palmiter RD . Identification of multiple metal regulatory elements in mouse metallothionein-I promoter by assaying synthetic sequences. Nature 1985; 317: 828–831.
Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515–520.
Herweijer H, Wolff JA . Progress and prospects: naked DNA gene transfer and therapy. Gene Therapy 2003; 10: 453–458.
Ruan H, Su H, Hu L, Lamborn KR, Kan YW, Deen DF . A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001; 3: 255–263.
Dalton TP, Bittel D, Andrews GK . Reversible activation of mouse metal response element-binding transcription factor 1 DNA binding involves zinc interaction with the zinc finger domain. Mol Cell Biol 1997; 17: 2781–2789.
Khachigian LM, Williams AJ, Collins T . Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 1995; 270: 27679–27686.
Dalton TP, Li Q, Bittel D, Liang L, Andrews GK . Oxidative stress activates metal-responsive transcription factor-1 binding activity. Occupancy in vivo of metal response elements in the metallothionein-I gene promoter. J Biol Chem 1996; 271: 26233–26241.
Acknowledgements
This work was supported by the National Research Laboratory Grant from the Korea Institute of Science and Technology Evaluation and Planning (M1-0412-00-0048) and the grants from the Korean Ministry of Health and Welfare (01-PJ1-PG1-01CH06-0003) and the Korea Science and Engineering Foundation (SRC, Molecular Therapy Research Center) to DK Kim.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, JY., Lee, YS., Kim, JM. et al. A novel chimeric promoter that is highly responsive to hypoxia and metals. Gene Ther 13, 857–868 (2006). https://doi.org/10.1038/sj.gt.3302728
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302728
Keywords
This article is cited by
-
Design of hypoxia responsive CRISPR-Cas9 for target gene regulation
Scientific Reports (2023)
-
Enhancing the tropism of bacteria via genetically programmed biosensors
Nature Biomedical Engineering (2021)
-
Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment
Journal of Investigative Dermatology (2013)
-
An Insult-Inducible Vector System Activated by Hypoxia and Oxidative Stress for Neuronal Gene Therapy
Translational Stroke Research (2011)